Fig. 2: 180-day risk for new diagnosis of endocarditis among patients with OUD or CocaineUD.
From: Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US
A Comparison of 180-day risk for a new diagnosis of endocarditis and infective endocarditis in patients with OUD in all populations and in three age groups (0–44, 45–64, ≥65). B Comparison of 180-day risk for a new diagnosis of endocarditis and infective endocarditis in patients with CocaineUD in all populations and in three age groups (0–44, 45–64, ≥65). COVID-19 (+) cohort – patients who contracted COVID-19 between 1/1/2020-4/18/2022 as documented in their EHRs in the TriNetX database. COVID-19 (−) cohort – who had no documented COVID-19 but had medical encounters with healthcare organizations between 1/1/2020-4/18/2022. COVID-19 (+) and COVID-19 (−) cohorts were propensity-score matched for demographics (actual age at index event, gender, race, ethnicity), adverse socioeconomic determinants of health, comorbidities, medical procedures, medications, and EHR-documented vaccination status. The outcomes (first-time diagnosis of endocarditis or acute or subacute infective endocarditis) were followed within 180-day time frame starting from the index event (COVID-19 infection for the COVID-19 (+) cohort and a recent medical encounter for the COVID-19 (−) cohort).
